JP2011523636A - うつ病に関するバイオマーカー - Google Patents

うつ病に関するバイオマーカー Download PDF

Info

Publication number
JP2011523636A
JP2011523636A JP2011508937A JP2011508937A JP2011523636A JP 2011523636 A JP2011523636 A JP 2011523636A JP 2011508937 A JP2011508937 A JP 2011508937A JP 2011508937 A JP2011508937 A JP 2011508937A JP 2011523636 A JP2011523636 A JP 2011523636A
Authority
JP
Japan
Prior art keywords
vivo imaging
polypeptide
polynucleotide
depression
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011508937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011523636A5 (https=
Inventor
ハンソン，ピーター
ヒスコック，ダンカン
モリス，クリス
トーマス，アラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of JP2011523636A publication Critical patent/JP2011523636A/ja
Publication of JP2011523636A5 publication Critical patent/JP2011523636A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
JP2011508937A 2008-05-15 2009-05-15 うつ病に関するバイオマーカー Pending JP2011523636A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0808834.6A GB0808834D0 (en) 2008-05-15 2008-05-15 Biomarkers for depression
GB0808834.6 2008-05-15
PCT/EP2009/055943 WO2009138499A2 (en) 2008-05-15 2009-05-15 Biomarkers for depression

Publications (2)

Publication Number Publication Date
JP2011523636A true JP2011523636A (ja) 2011-08-18
JP2011523636A5 JP2011523636A5 (https=) 2012-06-28

Family

ID=39571408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508937A Pending JP2011523636A (ja) 2008-05-15 2009-05-15 うつ病に関するバイオマーカー

Country Status (6)

Country Link
US (1) US20110064655A1 (https=)
EP (1) EP2281066A2 (https=)
JP (1) JP2011523636A (https=)
CN (1) CN102099492A (https=)
GB (1) GB0808834D0 (https=)
WO (1) WO2009138499A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523638A (ja) * 2008-05-15 2011-08-18 ジーイー・ヘルスケア・リミテッド うつ病に関するグルタミンバイオマーカー
JP2011523637A (ja) * 2008-05-15 2011-08-18 ジーイー・ヘルスケア・リミテッド うつ病に関するｇａｂａバイオマーカー

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9920371B2 (en) 2011-09-22 2018-03-20 Medvet Sciences Pty. Ltd. Screening method
CN103571849B (zh) * 2012-08-06 2015-05-13 北京市理化分析测试中心 用于检测抑郁症的基因及其检测方法和试剂盒
CN105177117A (zh) * 2015-07-03 2015-12-23 张理义 重症抑郁障碍生物标记物、筛选方法及试剂盒
KR102047479B1 (ko) * 2018-01-24 2019-11-21 전남대학교산학협력단 노년기우울증 검출방법 및 진단키트
CN113444802B (zh) * 2021-07-01 2024-02-06 复旦大学附属肿瘤医院 Htr1a在乳腺癌诊断、治疗和预后中的应用
WO2024215722A1 (en) * 2023-04-10 2024-10-17 Board Of Regents, The University Of Texas System Methods and compositions for diagnosing and treating depression and suicide risk

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047727A2 (en) * 2002-11-01 2004-06-10 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating mood disorders
US20050209181A1 (en) * 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders
US20070172830A1 (en) * 1998-05-12 2007-07-26 Human Genome Sciences, Inc. Antibodies to hhpen62 polypeptide
WO2008020435A2 (en) * 2006-08-15 2008-02-21 Quark Pharmaceuticals, Inc Compositions and methods for treatment of mood disorders
JP2011523637A (ja) * 2008-05-15 2011-08-18 ジーイー・ヘルスケア・リミテッド うつ病に関するｇａｂａバイオマーカー
JP2011523638A (ja) * 2008-05-15 2011-08-18 ジーイー・ヘルスケア・リミテッド うつ病に関するグルタミンバイオマーカー

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1766077T3 (da) * 2004-06-21 2012-07-16 Univ Leland Stanford Junior Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070172830A1 (en) * 1998-05-12 2007-07-26 Human Genome Sciences, Inc. Antibodies to hhpen62 polypeptide
WO2004047727A2 (en) * 2002-11-01 2004-06-10 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating mood disorders
US20050209181A1 (en) * 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders
WO2008020435A2 (en) * 2006-08-15 2008-02-21 Quark Pharmaceuticals, Inc Compositions and methods for treatment of mood disorders
JP2011523637A (ja) * 2008-05-15 2011-08-18 ジーイー・ヘルスケア・リミテッド うつ病に関するｇａｂａバイオマーカー
JP2011523638A (ja) * 2008-05-15 2011-08-18 ジーイー・ヘルスケア・リミテッド うつ病に関するグルタミンバイオマーカー

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013044975; Ｓｈｅｌｉｎｅ　ｅｔ　ａｌ．: ''Ｄｅｃｒｅａｓｅｄ　ｈｉｐｐｏｃａｍｐａｌ　５-ＨＴ（２Ａ）　ｒｅｃｅｐｔｏｒ　ｂｉｎｄｉｎｇ　ｉｎ　ｏｌｄｅｒ　ｄｅｐｒｅｓｓｅｄ　ｐａｔｉｅｎｔｓ　ｕｓｉｎｇ　［１８Ｆ］ａｌｔａｎｓｅｒｉｎ　ｐ' Ｎｅｕｒｏｐｓｙｃｈｏｐｈａｒｍａｃｏｌｏｇｙ ２９（１２）, 2004, ｐｐ．２２３５-４１ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523638A (ja) * 2008-05-15 2011-08-18 ジーイー・ヘルスケア・リミテッド うつ病に関するグルタミンバイオマーカー
JP2011523637A (ja) * 2008-05-15 2011-08-18 ジーイー・ヘルスケア・リミテッド うつ病に関するｇａｂａバイオマーカー

Also Published As

Publication number Publication date
US20110064655A1 (en) 2011-03-17
WO2009138499A3 (en) 2010-02-25
WO2009138499A2 (en) 2009-11-19
EP2281066A2 (en) 2011-02-09
CN102099492A (zh) 2011-06-15
GB0808834D0 (en) 2008-06-18

Similar Documents

Publication Publication Date Title
JP2011523636A (ja) うつ病に関するバイオマーカー
Farrell et al. DNA methylation differences at the glucocorticoid receptor gene in depression are related to functional alterations in hypothalamic–pituitary–adrenal axis activity and to early life emotional abuse
Malison et al. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl) tropane and single photon emission computed tomography
Arcos-Burgos et al. A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication
Laruelle Imaging dopamine transmission in schizophrenia: a review and meta-analysis
Wang et al. Positron emission tomography: applications in drug discovery and drug development
Kudo et al. 2-(2-[2-Dimethylaminothiazol-5-yl] ethenyl)-6-(2-[fluoro] ethoxy) benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients
Chauveau et al. Comparative evaluation of the translocator protein radioligands 11C-DPA-713, 18F-DPA-714, and 11C-PK11195 in a rat model of acute neuroinflammation
Scherfler et al. Striatal and cortical pre‐and postsynaptic dopaminergic dysfunction in sporadic parkin‐linked parkinsonism
Mitkus et al. Expression of oligodendrocyte-associated genes in dorsolateral prefrontal cortex of patients with schizophrenia
AU2006232338B2 (en) Methods for measuring the metabolism of neurally derived biomolecules in vivo
JP2011523637A (ja) うつ病に関するｇａｂａバイオマーカー
Masdeu Neuroimaging in psychiatric disorders
Shih et al. Parkinson’s disease and dopamine transporter neuroimaging: a critical review
CN106434870A (zh) ncRNA及其用途
Ho et al. Association study of serotonin transporter availability and SLC6A4 gene polymorphisms in patients with major depression
Hernandez et al. Abnormal expression of serotonin transporter mRNA in the frontal and temporal cortex of schizophrenics
Song et al. Advancements in noninvasive techniques for transplant rejection: from biomarker detection to molecular imaging
CN101490553A (zh) 用parp抑制剂治疗疾病的方法
JP2011523638A (ja) うつ病に関するグルタミンバイオマーカー
Smith et al. Translational research in late-life mood disorders: implications for future intervention and prevention research
CA2468651A1 (en) Detection of neurodegenerative diseases
Ibrahim et al. Early Onset Parkinsonism: Differential diagnosis and what not to miss
Brust et al. Neuroimaging of the serotonin transporter: possibilities and pitfalls
Beaino et al. Development and evaluation of [11C] DPA-813 and [18F] DPA-814: novel TSPO PET tracers insensitive to human single nucleotide polymorphism rs6971

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130910

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140304